Full Report

Industry in One Page

US for-profit hospital operators sell hospital and outpatient procedures to a small number of large payers — Medicare, state Medicaid programs, and a handful of commercial insurers — in regulated local markets where prices are largely negotiated, not posted. Profits exist because acute and surgical care is fixed-cost with high operating leverage: when revenue per case beats wage growth, margins expand sharply; when it doesn't, they collapse. The cycle today is dominated by three forces — the migration of surgery from hospitals into ambulatory surgery centers (ASCs), the expiry of enhanced Affordable Care Act exchange subsidies (EPTCs) at year-end 2025, and the One Big Beautiful Bill Act (OBBBA) signed July 2025 which tightens Medicaid eligibility and supplemental payments from 2027. The single thing newcomers misread: it is not a "growth" industry. Same-hospital admissions barely move year-to-year (THC Q4 2025: total admissions +0.4% YoY, utilization 49.8%); economic value is created by acuity mix, payer mix, and site shift to lower-cost outpatient settings — not by volume.

How This Industry Makes Money

Hospital operators bill per case — a discharge, a surgery, an emergency-department visit, an outpatient procedure — at rates that are heavily negotiated. Medicare pays via fixed Diagnosis-Related Group (DRG) prices set by CMS each year. Medicaid pays state-set rates topped up by supplemental payments (provider-tax and state-directed payment programs that recycle hospital fees back as enhanced reimbursement). Commercial managed-care payers — the source of ~70% of Tenet's hospital revenue — negotiate multi-year contracts, typically with annual escalators of 3–5%. The economics break into a hospital business and an ambulatory business with very different unit economics.

Where the bargaining power sits: with commercial payers (rate negotiations and narrow networks), physicians (they choose where to admit and which ASCs to invest in), and government (CMS rules and Medicaid supplemental payment rules can move multi-billion-dollar profit pools with one regulation). Hospitals get scale leverage on supplies and admin, but almost none on labor — wages are set by local market, union contracts (20% of THC hospital workforce), and state laws like California's healthcare-worker minimum wage (effective October 2024 with annual escalators through 2028).

Demand, Supply, and the Cycle

Underlying demand is demographic and durable — the 65+ population is growing, chronic-disease prevalence is rising, and procedures-per-capita inch up each decade. But aggregate demand for hospital admissions is essentially flat: in any given year US hospital occupancy hovers in the high 60s%, and Tenet's Q4 2025 licensed-bed utilization was 49.8% (down 70 bps YoY). The cycle does not look like an industrial cycle — it looks like a policy and payer cycle.

Two recent cycles are worth knowing because they bracket today's expectations: the 2020–2022 pandemic cycle (volume crash, then volume recovery + acute labor inflation that inverted hospital margins for many operators) and the 2014–2018 ACA expansion cycle (Medicaid expansion materially reduced uninsured admissions in expansion states, lifting margin in expansion-state operators while non-expansion-state operators got less benefit). Tenet sits more heavily in non-expansion states — over half of licensed beds are in Florida, South Carolina, Tennessee, and Texas where Medicaid was not expanded — which makes its hospital segment more sensitive to commercial coverage and exchange enrollment than peers concentrated in expansion states.

Competitive Structure

The US hospital market is locally concentrated, nationally fragmented, and bifurcated by ownership form. The five largest for-profit chains (HCA, Tenet, CHS, UHS, Encompass) together operate roughly 500–600 of the country's ~5,500 community hospitals; the rest are non-profit health systems (CommonSpirit, Ascension, AdventHealth, Kaiser), academic medical centers, public hospitals, and a long tail of independents. For-profits compete most directly with each other on capital allocation and ambulatory strategy, and with non-profits on labor and managed-care contracts in shared local markets — but not on tax economics: non-profits are exempt from federal income tax, state property tax, and have access to tax-exempt bond financing.

Two structural notes a newcomer should internalize. First, ambulatory surgery centers (ASCs) are a different competitive game from hospitals: ASCs are typically joint ventures with the physicians who use them, which makes physician syndication (not patient acquisition) the binding constraint on growth. Second, the non-profit overhang matters more than it looks — non-profits' tax exemption is roughly worth 200–400 bps of after-tax margin, which is why for-profits compete by scaling administrative functions (revenue cycle, supply chain) and rotating capital into ASC settings where non-profits have weaker physician relationships.

Regulation, Technology, and Rules of the Game

This is the most regulated industry on the S&P 500 outside of utilities and banks. Every revenue dollar passes through CMS rules, state Medicaid agencies, accreditation requirements, antifraud statutes, and HIPAA privacy rules. Three regulatory threads dominate the 2026 investor view.

The Metrics Professionals Watch

Forget generic ratios. The eight metrics below are what hospital and ASC analysts actually use, and they appear in every quarterly disclosure for THC, HCA, UHS, CYH, SGRY, and ACHC.

Where Tenet Healthcare Corporation Fits

Tenet is the only US listed for-profit hospital operator with a scaled ambulatory surgery platform — that is its defining characteristic. The Hospital Operations segment (50 acute hospitals + 132 outpatient sites + Conifer revenue cycle) places Tenet in the second-tier scale group with UHS and CYH, well behind HCA. The Ambulatory Care segment (USPI: 533 ASCs + 26 surgical hospitals across 37 states) makes Tenet effectively a hybrid of HCA-style hospital operator and Surgery Partners-style ambulatory pure-play, sitting on top of the largest national ASC platform.

What to Watch First

Five-to-seven signals that quickly tell whether the industry backdrop is helping or hurting Tenet:

Bottom Line

Tenet is a low-margin hospital chain wrapped around a high-margin ambulatory surgery business. USPI — 533 physician-syndicated ASCs and 26 surgical hospitals — earns a ~40% segment EBITDA margin and now contributes ~44% of consolidated adjusted EBITDA on ~24% of revenue. The hospital segment, after three years of selective divestitures, is a smaller, denser, ~16% adj EBITDA margin business that prints cash but faces real 2026–2027 payer-mix headwinds.

The market most often gets two things wrong here. Underestimated: the durability of USPI's ~40% margins and Tenet's reset cost base — consolidated adj EBITDA margin is now 21.4%, up from ~12% in 2018. Overestimated: the hospital segment as a growth story; same-hospital admissions grew 1.7% in 2025 and are guided to 1–2% in 2026 against a $250M EBITDA hit from ACA exchange-subsidy expiry. Whether the stock looks cheap or expensive depends almost entirely on what multiple USPI deserves vs. SGRY.

1. How This Business Actually Works

Tenet runs two distinct profit engines that share almost nothing economically except a corporate cost stack and a managed-care contracting team. The Hospital Operations segment is a high-fixed-cost, scale-and-payer-mix business: 50 acute-care hospitals (12,494 licensed beds) plus 132 outpatient sites, primarily clustered in Texas (San Antonio, El Paso), Florida, Arizona, and Detroit. USPI is a capital-light, physician-joint-venture business: Tenet typically owns a 50–80% economic stake alongside the local physicians who drive case volume. The two segments earn their money in fundamentally different ways.

The mechanics that matter on each side:

Hospital Operations — a payer-mix and acuity machine. Revenue per adjusted admission is the single most important line. In FY2025 it grew 5.3% same-hospital while admissions grew only 1.7%. Wages, nursing, and supplies are 76% of the cost base, mostly variable to admissions, but with a wage floor that resets every year (CA healthcare-worker minimum-wage law, union contracts at 27 hospitals, 31% of staff are nurses). Profitability lives in the spread between negotiated commercial rates (3–5% annual escalators, 70% of revenue) and labor + supply cost growth — and in moving cases out of inpatient into the outpatient sites that sit inside the same segment, where margins are structurally higher. Tenet's 2024 hospital divestitures (~14 hospitals across SC, CA, AL) were not a cost cut; they were a margin-mix decision. Same-hospital salaries-wages-benefits was 46.3% of revenue in FY2025, down 140 bps from 2024.

USPI — a physician-syndication compounding machine. USPI doesn't compete for patients; it competes for physicians. The local orthopedic group, cardiologists, gastroenterologists buy in alongside USPI as JV partners and bring their cases. Once a center has the right physicians, growth comes from (a) raising acuity — moving total joints, complex spine, more cardiology into the ASC as CMS phases procedures off the inpatient-only list, (b) negotiated commercial rate increases (3–5%), (c) acquiring or building new centers (35 added in 2025 for $350M of capital), and (d) M&A. Same-facility revenue grew 7.5% in 2025, well ahead of management's "long-term 3–6%" framework, with double-digit growth in same-store joint replacements. Because Tenet doesn't own 100% of USPI's facilities, a meaningful share of segment EBITDA flows out to noncontrolling-interest holders — distributions to NCI were ~$224M in Q4 2025 alone, and 2026 guidance shows FCF after NCI of $1.6–1.83B against total FCF of $2.5–2.8B (so ~30% of FCF is non-controlling).

Conifer — a smaller third leg in transition. Conifer is Tenet's revenue cycle BPO arm with ~$25B of client patient revenue under management and a 5,600-person Manila Global Business Center. Tenet bought back the 23.8% CommonSpirit JV stake on January 1, 2026 for $540M, retired $885M of related obligations, and accelerated $1.9B of contract cash flows (after-tax NPV of the deal: ~$1.1B per management). The CommonSpirit master services agreement winds down December 31, 2026 — meaning Conifer revenue will be smaller from 2027, but margin and free-cash conversion improve materially. Treat Conifer as "small-but-clean" (~$200M EBITDA, ~25%+ margin, ~5% of consolidated EBITDA).

2. The Playing Field

Five public peers anchor the read on Tenet, and they are not all hospital chains. HCA is the scale benchmark for hospitals (3.6× Tenet's revenue, materially higher hospital margins). UHS and CYH are the cleanest reads on second-tier hospital economics — UHS as the well-managed comp, CYH as the textbook stressed-comp (negative book equity, 5.6× net debt / EBITDA). SGRY is the only listed pure-play comp for USPI — same syndicated-physician model, similar acuity migration, ~9.4× EV/EBITDA. ACHC is the behavioral-hospital comp, currently impaired and not a useful margin read for 2025.

The peer comparison reveals three things that matter. First, Tenet's consolidated margin (21.4%) is essentially equal to HCA's (21.8%) — a remarkable convergence given HCA is 3.6× larger and has historically dominated on scale. The reason is mix: USPI's 40% segment margin pulls Tenet's blend up, while HCA's hospital-heavier mix anchors its blend lower despite a stronger hospital franchise. Second, Tenet trades at a meaningful discount to both HCA (8.6×) and SGRY (9.4×) despite having both businesses inside it — a discount that only makes sense if the market is treating it primarily as a hospital chain (next to UHS at 5.3× and CYH at 5.5×). Third, Tenet's leverage (2.25× net debt / EBITDA) is now the lowest among peers ex-UHS — a structural change from 2018 when it ran at 6.2×. The deleveraging is what unlocked the buyback program (22% of shares retired since 2022).

What the best peer does better: HCA generates more cash per hospital because of denser local market shares (often #1 or #2 by share in its top markets) and a longer track record of physician alignment. SGRY has a more aggressive acquisition cadence at USPI's exact target size band but at the cost of FCF and leverage discipline. Tenet sits between them — better physician network than CYH/UHS, lower hospital concentration than HCA, more measured capital allocation than SGRY.

3. Is This Business Cyclical?

Tenet's cycle is policy-driven, not industrial. Industry-wide hospital occupancy moves a few hundred basis points across a full economic cycle; same-hospital admissions for major operators rarely deviate more than 2–3% from trend in any given year. What does move sharply is payer mix, and payer mix is set by federal and state policy (Medicaid expansion, ACA exchange subsidies, OBBBA, DSH adjustments), not by GDP.

Two recent episodes bracket the range of outcomes for Tenet's hospital segment. The 2020–2022 pandemic-and-labor cycle crushed margins industry-wide as nursing wages spiked (contract labor reached double digits as a percentage of total wages at most operators); Tenet's consolidated margin compressed from 17.8% in 2021 back to 15.3% in 2022 before recovering. The 2014–2018 ACA expansion cycle lifted commercial coverage in expansion states and reduced uninsured admissions — a tailwind that disproportionately bypassed Tenet because over half its licensed beds sit in non-expansion states (FL, SC, TN, TX). That same geographic tilt is now the source of acute downside: those four states are exactly where the expired enhanced premium tax credits are causing the sharpest exchange-enrollment declines.

The bigger policy hit comes in 2027 with OBBBA Medicaid changes (work requirements, supplemental-payment caps, eligibility checks) and the rescheduled Medicaid DSH cuts. Management has not yet quantified the OBBBA impact; CBO sees millions losing coverage by 2034. The right way to think about cycle exposure is two layers: 2026 is mostly a payer-mix problem (commercial-to-uninsured shift); 2027 is a Medicaid-funding problem (lower supplemental payments, especially in non-expansion states). USPI is largely insulated from both — its commercial/Medicare-heavy mix and ASC-only payment structure don't move with Medicaid policy. Hospital is exposed to both.

4. The Metrics That Actually Matter

Forget P/E and price-to-sales. The five metrics below are what hospital and ASC analysts actually use, and they appear every quarter for THC and its peers.

Two things to note about returns on capital. The FY2024 spike (ROIC 18.3%, ROE 57.8%) is mostly the $2.92B GAAP gain on hospital divestitures, not an operating step-change. The FY2025 reading (ROIC 11.4%, ROA 9.4%) is the cleaner picture — a real improvement from the high-single-digits of 2018–2023, but not an HCA-quality return on capital. The reason is structural: hospital businesses earn lower ROIC than ambulatory because of the goodwill burden ($11.2B at year-end, ~38% of total assets) and the heavier physical footprint. USPI alone almost certainly earns a >25% ROIC on its newer cohorts of acquired centers; the consolidated number is dragged down by hospital goodwill.

5. What Is This Business Worth?

Tenet should be valued sum-of-the-parts, because the two main segments earn different multiples for different reasons. Hospital Operations is a regulated, payer-mix-sensitive, mid-teens-margin acute-care chain that trades in the 5–7× adj EBITDA band (UHS, CYH, HCA-discount). USPI is an ASC platform with 40% margins, mid-single-digit organic growth, and an active M&A pipeline — the closest comp (SGRY) trades at 9.4× and has weaker margins, lower scale, and more leverage. Treating them as one $4.6B EBITDA stream and applying a hospital multiple — which the market often does — systematically undervalues USPI. Treating them as one $4.6B EBITDA stream and applying an ASC multiple — which sell-side bulls do — systematically overvalues the hospital piece going into 2026–2027 policy headwinds.

Binder Error: Set operations can only apply to expressions with the same number of result columns

The biggest single judgment call is what multiple USPI deserves. Three reasons it could deserve a SGRY-plus premium: scale (533 ASCs vs. SGRY's ~150), better same-facility growth (7.5% vs. SGRY ~5%), and FCF discipline (Tenet generated $2.5B in FCF in 2025 vs. SGRY ~zero). Three reasons it could deserve a discount: most of the ASC platform's optionality (inpatient-only list phase-out, joint-replacement migration) is already baked into 2025 results; ~30% of segment economics flow to physician-JV partners; and segment EBITDA is partially elevated by acquisition mix.

The biggest hospital-side judgment call is the durability of the 16% margin. Tenet got there by selling 14 lower-margin hospitals and concentrating in higher-acuity Texas/Florida markets. That mix is structurally better than 2018, but the 1.7% same-hospital admission growth is also barely above demographic baseline — meaning margin holds only as long as revenue per adjusted admission keeps growing 4–5%. That requires acuity to keep migrating up, payer-mix shifts not to swamp the gain, and labor cost growth to stay at or below 4%. All three conditions held in 2025. EPTC expiry threatens the second; OBBBA threatens the first via Medicaid funding cuts.

6. What I'd Tell a Young Analyst

Five things to internalize, in order of importance.

1. Stop reading consolidated numbers. Read segment numbers. Every important question about Tenet — what's it worth, where's the cycle, what's the moat — requires separating USPI from Hospital. The consolidated 21.4% margin is a blend that doesn't exist anywhere inside the company; in reality you have a 40%-margin business attached to a 16%-margin business. Build the model with two columns from the start.

2. The single number that resolves the bull-bear debate is USPI same-facility revenue growth. If it stays above the 6% top end of management's long-term band, the SOTP math compounds favorably and the stock is cheap. If it falls below 5% for two quarters running, the SGRY-style multiple is at risk and the stock is probably fairly valued. Track it monthly via investor-day disclosures and quarterly press releases — and watch SGRY's number as a confirming signal.

3. The hospital segment is in its "test the reset" phase. Tenet sold ~14 hospitals in 2024, kept the high-acuity, urban/suburban concentrations (San Antonio, El Paso, Florida, Detroit), and reset the cost base. 2025 worked. 2026 has a quantified $250M EBITDA headwind from EPTC expiry. 2027 has an unquantified Medicaid OBBBA hit. If management defends the 16% segment margin through both, it confirms the reset is real and the segment deserves a HCA-discount multiple, not a UHS/CYH multiple. If margins compress more than 100 bps, the reset thesis is wounded.

4. The market is most likely missing the structural change in cash flow. FCF was $321M in FY2022; $2.53B in FY2025; guided to $2.5–2.8B for 2026 with $1.6–1.83B after NCI distributions. Even at the post-NCI midpoint, that's a ~10% FCF yield on equity at $187 — high for any healthcare business with these growth dynamics. The buyback cadence (22% of shares retired since 2022 for $2.5B) implies management agrees. Don't fixate on the EPS growth rate; fixate on the per-share cash flow trajectory.

5. Three things would change the thesis materially.

• USPI same-facility growth slowing to 3–4% sustained would shift the SOTP math 15–20% lower and remove the rerate case.
• An OBBBA implementation that meaningfully caps state-directed payments before management can offset would compress hospital EBITDA by $300–500M annually and re-leverage the balance sheet.
• A site-neutral Medicare payment reform passed by Congress would benefit USPI (its ASC payments are already lower) but hurt Tenet's hospital outpatient departments — net effect probably negative for the consolidated story but mixed by segment.

Watch for the first signs of any of these in Q1–Q2 2026 commentary. Beyond that, the rest of the noise — quarterly volume jitter, weather, flu season, individual market disputes — does not change the investment case.

Competitive Bottom Line

Tenet has one real moat and one commodity business, and the market still prices it as if both halves were commodities. The moat is USPI, the largest national ambulatory surgery platform by facility count (533 ASCs + 26 surgical hospitals across 37 states) — a physician-syndication network that is genuinely hard to replicate because the binding constraint is not capital but local orthopedic, GI, and cardiology partnerships. The commodity is the Hospital Operations segment, which competes head-to-head with HCA in San Antonio, El Paso, and Florida and is a price-taker on commercial managed-care contracts, Medicaid supplemental payments, and California labor laws.

The single competitor that matters most is HCA Healthcare: 3.6× the revenue, denser local market shares, materially better hospital-segment margin, and the only peer with a strategic ASC build (Sarah Cannon network) sized to threaten USPI's growth runway. Behind HCA, the relevant pressure on USPI is not from listed peers — it is from private vertical integrators: Optum/SCA Health (UnitedHealth-owned) and AmSurg/Envision-derived rollups, both of which Surgery Partners explicitly names as direct ASC competitors in its FY2025 10-K. The peer set delivers the read on Tenet's hospital margin durability; the unlisted competitors deliver the read on USPI's pricing and physician-retention runway.

The Right Peer Set

Five public companies anchor the read on Tenet, organized by which segment they inform. HCA, UHS, and CYH triangulate Hospital Operations across three points of the operating spectrum (best-in-class scale, second-tier execution, stressed leverage). SGRY is the only listed pure-play comparable to USPI's ambulatory model and the cleanest market read on ASC unit economics. ACHC is the behavioral-hospital adjacent comp and the cycle-stress test for specialty acute care.

The bubble chart reveals the central pricing puzzle. Tenet's blended margin (21.4%) is essentially equal to HCA's (21.8%) and well above UHS (16%), CYH (15%), and SGRY (17.7%) — yet Tenet trades at the same multiple as the stressed mid-tier hospital peers, not at the HCA scale-leader multiple or the SGRY ASC-pure-play multiple. That dislocation only makes sense if the market is treating Tenet purely as a hospital chain and assigning zero premium for the USPI ambulatory mix that is doing the work on margin. The peer set is precisely calibrated to tell you which read is correct — by comparing segment-level economics rather than blended consolidated print.

Where The Company Wins

Tenet wins on four specific dimensions, each tied to a measurable line and a comparable peer.

Win 1: Only listed for-profit with a scaled ASC platform

USPI's 533 ASCs plus 26 surgical hospitals across 37 states is the largest national ambulatory footprint among public for-profits. HCA, the largest hospital operator, has 121 ASCs plus 31 endoscopy centers — meaningful but ~28% of USPI's facility count. Surgery Partners, the only listed ASC pure-play, has 157 ASCs + 19 surgical hospitals — ~33% of USPI's facility count. This matters because ASC growth is gated by physician partnerships, not capital, and the largest national operator has the highest probability of being the chosen platform partner when an orthopedic group decides to syndicate. The FY2025 10-K cites 35 acquired centers and 87 service-line additions (per Industry tab) as the operating cadence.

Win 2: Mix-driven margin parity with HCA at a fraction of the scale

Tenet's consolidated 21.4% adjusted EBITDA margin is almost identical to HCA's 21.8% GAAP-derived margin, despite Tenet being 1/3.6 the revenue. The reason is segment mix: USPI's ~40% segment EBITDA margin pulls Tenet's blend up, while HCA's hospital-heavier mix anchors its blend lower (its hospitals are still better-run on a like-for-like basis, but the consolidated print converges). Among hospital-focused peers, the gap is wider: UHS at 16.0%, CYH at 15.3%, SGRY at 17.7% — Tenet beats all three on consolidated margin.

The chart reveals what the consolidated number obscures: USPI by itself prints at 39.2% — more than double SGRY's blended 17.7% and roughly 2.5× UHS or CYH. This is the moat. SGRY is Tenet's closest economic parallel on the ambulatory side, but does it at considerably lower margin and with materially higher leverage (6.4× net debt / EBITDA vs. Tenet 2.25×).

Win 3: Cleanest balance sheet among scale peers

Tenet's 2.25× net debt / EBITDA (Q4 2025) is the lowest among scale peers ex-UHS. CYH runs at 5.5×+ with negative book equity. SGRY operates at 6.4×. ACHC sits around 3.5× but is impaired. HCA at 3.0× is close, but HCA is materially larger and produces more absolute FCF. The deleveraging story matters for two reasons: it gates the buyback cadence (Tenet retired ~22% of shares since 2022) and it lowers refinancing risk in an environment where UHS is explicitly flagging the 2026 refinancing of its 1.65% senior notes at "significantly higher interest rates" in its FY2025 MD&A.

Win 4: Cash conversion that the others can't match

Free cash flow was $321M in FY2022 and reached $2.53B in FY2025, with management guiding to $2.5–2.8B for 2026. SGRY converts almost zero of its EBITDA to FCF (high capex on de novo development). HCA generates ~$7.7B of FCF on $16.5B EBITDA (47% conversion) — strong but on a much larger denominator. Tenet converts ~55% of consolidated adjusted EBITDA to FCF before NCI distributions; ~35% after the ~$700M of annual NCI payments to physician partners. The post-NCI yield (~10% on equity) is the cleanest like-for-like measure and Tenet wins it on a per-dollar basis.

Where Competitors Are Better

Four specific gaps where Tenet trails. Be precise about which competitor is better and why — generic "competition is intense" language hides what matters.

Gap 1: HCA dominates hospital-segment density and physician alignment

HCA operates 190 hospitals (179 acute) across 19 states with much higher local market share in its core markets — Houston, Nashville, Denver, Las Vegas, Salt Lake City, multiple Florida MSAs. In shared markets like San Antonio (where Tenet's Baptist Health System overlaps with HCA-Methodist), HCA typically holds the #1 or #2 share position. The result is structural: HCA negotiates managed-care contracts with embedded leverage Tenet cannot match, and its same-facility hospital margin runs roughly 200–300 bps above Tenet's hospital segment (HCA segment disclosure does not separate, but consolidated 21.8% with smaller ASC contribution implies a hospital margin around 20%, vs. Tenet hospital segment 15.7%). HCA is also rolling out a single EHR platform across all facilities — a multi-year operating-leverage program Tenet has not signaled at the same scale.

Gap 2: SGRY's pure-play multiple is the gap Tenet cannot close

Surgery Partners trades at 9.4× EV/EBITDA on the same 17.7% margin business that Tenet's USPI segment runs at 39.2% margin. SGRY's higher multiple reflects (a) pure-play exposure to ASC migration with no hospital drag, (b) explicit physician-partner balance-sheet structure, and (c) higher M&A cadence relative to its size. Tenet's USPI is structurally better but earns no rerate inside the consolidated capital structure because the market discounts the hospital piece into the blended multiple. SGRY's recent FY2025 10-K explicitly names HCA, AmSurg, and Tenet as ASC competitors — confirming the market is thinking about USPI as a pure-play asset, not as a Tenet attribute.

Gap 3: UHS's behavioral diversification and lower leverage

UHS at 1.6× net debt / EBITDA is less levered than Tenet (2.25×) and runs a 339-facility behavioral health business across 39 states + UK + PR — a category Tenet exited via 2017–2020 divestitures. The behavioral segment is structurally counter-cyclical to acute-care payer mix and provides ~40% of UHS EBITDA. Behavioral was the area where Tenet historically underperformed (Aspire/Vanguard divestiture history, several DOJ settlements) and UHS's continued footprint is a strategic option Tenet no longer has. ACHC, the pure-play behavioral peer, is currently impaired (FY2025 EBITDA negative on facility goodwill writedowns) — meaning UHS is also taking share inside its own category.

Gap 4: SGRY and HCA out-acquire on ASC tuck-ins per dollar of revenue

SGRY's acquisition cadence (35–45 centers per year on a ~$3.2B revenue base) is materially higher per dollar of revenue than Tenet's (USPI added ~35 centers in 2025 on a ~$5.2B segment revenue). HCA has been quietly building Sarah Cannon Surgical Network as an ASC layer beneath its hospital footprint. Both are buying centers in geographies Tenet considers core (Texas, Florida, Tennessee), and both are willing to pay high multiples for physician relationships in priority markets. Tenet's discipline on price preserves margin but cedes some growth runway in metros where HCA-Sarah Cannon or SGRY locks in physicians first.

Threat Map

Six threats grouped by where they hit (USPI side, Hospital side, or both). The non-listed competitors — Optum/SCA Health, AmSurg/Envision-derived rollups, Apollo's LifePoint — are explicitly named as ASC competitors in Surgery Partners' FY2025 10-K and are the most underestimated category in the public peer comparison.

Moat Watchpoints

Five measurable signals that tell you whether Tenet's competitive position is improving or weakening. Each has a quarterly disclosure source so investors can track without a Bloomberg terminal.

Current Setup & Catalysts

Current Setup in One Page

The stock is sitting at $187 five trading days after a clean Q1 2026 beat (EPS $4.82 vs $4.21 consensus, EBITDA $1.16B in line) on which management raised the FY2026 EPS guide to $16.38–$18.68 — yet THC is still 23% below the February high of $244.80, below both the 50-day and 200-day SMA, and trading at a 13% discount to the consensus $240 price target. The market is doing two things at once: digesting a known $250M EPTC headwind on the hospital book that management has already embedded in 2026 guidance, and pre-pricing an unquantified 2027 OBBBA Medicaid hit that has frozen the FY2027 consensus at $17.76 (essentially flat on the FY2026 mid-point of $17.53). The question for the next six months is whether USPI's same-facility growth (5.3% in Q1, target 3–6%) and hospital cost discipline (SWB 40.5% of revenue) hold the line through Q2/Q3 prints — or whether payer-mix erosion bleeds into hospital revenue per adjusted admission and forces a guide cut.

What Changed in the Last 3-6 Months

The narrative arc. Six months ago, the debate was about whether USPI's 7.5% same-facility growth and 21.4% consolidated EBITDA margin were durable enough to earn a SOTP rerate. Today, after the FY2026 guide and Q1 print, the debate has shifted: USPI is doing its job (EBITDA +6% at 36.7% margin) but the hospital book has gone from "stable" to "questioned" — Q1 hospital revenue grew only 0.5% with same-hospital revenue per adjusted admission down 1.5% on payer-mix. The unresolved questions are (1) does the 10% Q1 exchange admission decline foreshadow a smaller-than-guided $250M hit (bullish guide reset) or does H2 disenrollment catch up; (2) when CMS/Treasury issue OBBBA Medicaid implementation rules, how punitive are the state-directed payment caps for non-expansion states (FL/SC/TN/TX, where Tenet has 50%+ of beds); (3) does Conifer announce the 2027 client backfill before the storyline becomes "Conifer is shrinking." The market has marked the stock down 23% from the February high not because anyone has changed the FY2026 number — they have actually raised it — but because the FY2027 consensus refuses to move ($17.76 vs $17.72 FY2026), and that flat-line is what investors now have to underwrite or reject.

What the Market Is Watching Now

This is the live debate going into Q2. None of it is academic: the FY2027 EPS line that consensus refuses to grow ($17.76 vs $17.72 FY2026) is exactly the line that resolves only when the market sees how OBBBA implementation, Conifer backfill, and USPI growth land on actual 2027 EPS — and the first reads on all three come inside the next six months.

Ranked Catalyst Timeline

The calendar is moderately full but the single binary is OBBBA Medicaid implementation rules in H2 2026. Q2/Q3 earnings will tell us whether the FY2026 guide is intact; OBBBA tells us whether the FY2027 EPS line ($17.76 consensus, flat to FY2026) is the right anchor or 20% too high. Everything else is supporting evidence.

Impact Matrix

Next 90 Days

The 90-day window is dominated by Q2 earnings in late July and the CMS CY2027 OPPS proposed rule a couple of weeks earlier. Between now and mid-July there is no hard-dated catalyst that would force consensus to move; investors should watch the tape (a reclaim of the 50-day SMA at ~$205 is the technical add signal; a close below $172 puts the bear $135 target in play) and any incremental OBBBA implementation chatter from CMS. The next Conifer client-win announcement, an unexpected payer dispute escalation, or a sub-$190 buyback disclosure would each move the stock without a calendar peg.

What Would Change the View

The next six months are a tractable test bench. First, two consecutive USPI same-facility prints at 5%+ with hospital RPAA stabilizing to flat would force a re-mark of the FY2027 consensus EPS (currently flat YoY at $17.76) and reopen the SOTP rerate that has been on hold since the February high — that is the bull's only path back to $245. Second, OBBBA Medicaid implementation rules issued in H2 2026 that bind state-directed payment caps in non-expansion states starting 2027 would lock in the bear's $300–500M FY2027 hospital EBITDA hit — that is what justifies the $135 downside without needing USPI to break. Third, the absence of any Conifer 2027 client-backfill commentary by Q3 would convert the $1.9B CommonSpirit "accretion" into a one-time event in the market's mind and put pressure on the 2027 cash-flow guide. These three signals — USPI same-fac, OBBBA rules, Conifer backfill — are what the next two earnings cycles are about. Everything else (PAO transition, conferences, payer disputes, St. Vincent remediation costs, the SEC FOIA matter) is noise unless one of them generates an unexpected disclosure.

Bull and Bear

Verdict: Lean Long, Wait For Confirmation - the SOTP gap and buyback flywheel are real, but two unresolved swing factors (USPI same-facility growth and the SEC FOIA 7(A) enforcement matter) sit directly on top of the rerate path. The bull's central claim - that USPI is a SGRY-comp ambulatory platform mispriced inside a hospital wrapper - is supported by six years of 3-6%+ same-facility growth and a 21-percentage-point margin gap. The bear's central claim - that USPI's M&A pace has already slipped (533 vs. 575-600 promise) and that 2026-2028 stacks EPTC + OBBBA + site-neutral on the hospital book - is also supported by management's own admissions cadence trim and confirmed FOIA exemption. The decisive variable is observable in two quarters, not five years; the right posture is to keep the name on a tight watchlist and let Q3-Q4 2026 USPI prints break the tie.

Bull Case

Bull's price target: $245 (12-18 months). SOTP method - USPI $20B (10x $2.0B EBITDA), Hospital Operations $16B (6.3x $2.5B EBITDA), Conifer $1.5B (7.5x $200M EBITDA), less $10.3B net debt and ~$2B NCI capitalization burden ≈ $25B equity / ~85M post-buyback diluted shares ≈ $245. Cross-checked against sell-side $240 consensus. Disconfirming signal: USPI same-facility revenue growth below 5% for two consecutive quarters - the moat thesis breaks and USPI no longer earns a premium to SGRY.

Bear Case

Bear's downside target: $135 (12-18 months). SOTP on stressed FY26E - USPI $13.6B (7x $1.95B EBITDA, NCI haircut), Hospital $11.0B (5x $2.2B EBITDA post-EPTC + partial OBBBA), Conifer $1.0B (5x $200M post-CommonSpirit), less ~$14B net debt and NCI = $11.6B equity / 87M shares ≈ $133, rounded to $135. Cross-checked against the 52-week low of $137. Cover signal: USPI same-facility growth holding 6%+ through Q4 2026 AND public closure of the SEC enforcement matter without action AND OBBBA implementation slipping past 2028.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. The bull carries more weight on the substance: a SOTP framework that brackets equity at $19-27B against a $17B market cap is hard to dismiss, the FCF step-change to $2.5B is documented across three years, and a 2.25x leverage balance sheet with no maturities until late 2027 buys time through the policy fog. The single most important tension is the USPI moat - both sides agree the $245 outcome and the $135 outcome both pivot on whether USPI same-facility growth holds 6%+ or breaks below 5% over the next two prints, which is precisely why the right posture is to wait the two quarters rather than commit ahead of the print. The bear could still be right if the 533-vs-600 unit miss is the first crack in a payer-controlled competitive squeeze (Optum/SCA), or if the SEC FOIA 7(A) matter escalates into a $675-845M action - either is a re-rate event independent of fundamentals. The condition that would change this verdict to a clean Lean Long is the combination of USPI same-facility printing 6%+ in Q3 2026 AND the SEC enforcement matter resolving without action; conversely, USPI sub-5% for two quarters or an SEC charge would flip the call to Avoid. The 30% upside-to-target is real, but the path runs through evidence the calendar will deliver, so the institutional move is to keep the name on a short watchlist rather than sizing in front of it.

Moat in One Page

Verdict: Narrow moat — concentrated in USPI, almost absent in Hospital Operations. Tenet is two businesses bolted together, and only one of them has a durable, company-specific advantage. The Ambulatory Care segment (USPI: 535+ ASCs and surgical hospitals across 37 states, ~11,000 affiliated physicians of which ~6,000 are equity partners) earns a 39.2% segment EBITDA margin versus 17.7% at the only listed pure-play comparable (Surgery Partners), with same-facility revenue growing 7.5% in FY2025. That gap is too wide and too durable (six straight years above the 3–6% long-term band) to be explained by execution alone — it points to a real intangible asset (physician-partner network density) plus a scale-and-density cost advantage that an entrant cannot replicate without a decade of capital and physician relationships.

The Hospital Operations segment, which still produces ~76% of revenue and ~56% of EBITDA, is a commodity payer-mix machine. Tenet is a price-taker on Medicaid supplemental payments, OBBBA, California labor laws, and managed-care rate negotiations where HCA holds the #1/#2 share in most shared markets. The hospital segment's 15.7% margin is decent, but the gap to HCA's roughly 20% hospital margin is structural (scale, density), not a moat for Tenet. What protects this business is USPI, and only USPI — and the biggest weakness is that ~30% of segment cash flow flows to physician-JV minority partners, and the most credible attacker (Optum/SCA Health, owned by UnitedHealth) is also the largest US commercial payer.

What "moat" means here. A moat is a durable, company-specific advantage that lets the company keep pricing power, retention, share, or returns above what the average competitor can earn — not just because the industry is attractive, but because this company has something that those competitors can't easily copy. "Narrow" means the advantage exists and is measurable, but it is segment-specific or vulnerable enough that a five-year forward forecast cannot lean on it the way it could for a wide-moat business.

Sources of Advantage

Five candidate sources, evaluated against evidence. Three carry weight; two do not.

Why these categories. A moat checklist asks: switching costs, network effects, scale/cost advantage, intangibles (brand, patents, licenses, regulatory), distribution, embedded workflow, local density, and capital intensity. For a hospital and ASC operator, the four that ever matter are physician relationships, scale density, regulatory licensing (CON laws, Medicare provider numbers), and embedded workflow (RCM). Tenet has weak-to-none across CON licensing and Medicare numbers — those are industry-wide barriers, not company-specific.

Evidence the Moat Works

Eight evidence items, drawn from filings and peer disclosures. The first four support the USPI moat; items five and six refute the broader corporate moat; items seven and eight are mixed.

The chart is the single most important piece of evidence on this page. USPI's 39.2% segment margin is more than double SGRY's 17.7% blended margin — and SGRY's economics include the same physician-syndication model, the same case-mix migration, and the same payer environment. The 21-percentage-point gap is the moat in numbers. Strip out USPI, and Tenet's hospital segment (15.7%) is essentially CYH (15.3%) — confirming there is no separate hospital-side advantage hidden in the consolidated print.

Where the Moat Is Weak or Unproven

Five places where the advantage could be exaggerated, cyclical, or borrowed from industry structure.

1. The hospital segment is a commodity wrapped around a moat. Three-quarters of Tenet's revenue and ~56% of EBITDA come from a business with no proven company-specific advantage. The 15.7% segment margin is below HCA's roughly 20% hospital margin, the same-hospital admissions growth is barely above demographic baseline, and Tenet is more exposed than peers to the 2026 EPTC headwind (>50% of beds in non-expansion states) and the 2027 OBBBA Medicaid headwind. A consolidated moat rating of "narrow" is generous if you weight by revenue rather than EBITDA growth.

2. The USPI moat is shared with physician partners — about 30% of cash leaks out before reaching shareholders. Noncontrolling-interest distributions ran ~$700M in FY2025; FY2026 guidance shows FCF after NCI of $1.6–1.83B against gross FCF of $2.5–2.8B. The economic moat exists, but the public shareholder owns ~70% of it. SGRY structures its physician partners differently, partly explaining its higher implied valuation per dollar of (lower) margin.

3. The acuity-migration tailwind is industry-wide, not USPI-specific. CMS has been moving procedures off the inpatient-only list for a decade — joint replacements, complex spine, more cardiology — and this benefits every ASC operator. A meaningful slice of USPI's 7.5% same-facility growth is a tide that lifts all ASC boats. If you strip the migration tailwind out, USPI's organic growth is closer to the 3–4% lower band of management's long-term framework, and the moat looks narrower.

4. The most credible attacker on the USPI side is also the largest US commercial payer. Optum/SCA Health (UnitedHealth) is named as a national ASC competitor in Surgery Partners' FY2025 10-K. UnitedHealth owns the payer (UHC), the physician channel (Optum Health, ~90,000 employed physicians), and the ASC operator (SCA Health, the second-largest US ASC platform after USPI). In any market where UNH offers a narrow network, USPI ASCs can be excluded. There is no public evidence yet that this is happening at scale — but it is the single most important watch signal.

5. Multi-decade history of regulatory exposure caps the certainty premium. Tenet has paid more than $700M in False Claims Act and DOJ settlements since 2006 (a $513M FCA settlement in 2022 alone, plus $54M, $42M, $30M earlier). A short report in June 2025 (Fuzzy Panda Research) cited an SEC FOIA appeal showing an active enforcement matter and alleged $675–845M in potential Medicare/Medicaid fines. Compensation ties to Adjusted EBITDA, FCF, and ROIC — exactly the metrics under scrutiny. None of this changes the operational moat, but it means the durability rating cannot be "high" until the enforcement landscape clears.

Moat vs Competitors

Five competitors, evaluated on what each does better and where each is weaker. The relevant peer set splits across two segments — USPI competes against Optum/SCA, AmSurg/PE rollups, HCA Sarah Cannon, and SGRY; Hospital Operations competes against HCA, UHS, CYH, and non-profits.

Durability Under Stress

A moat that hasn't survived stress is a hypothesis. The USPI model has lived through one full cycle (2015–2025) including COVID, but has not yet been tested by a payer-led narrow-network attack or major regulatory shift. Six stress scenarios with what we know.

The chart makes the durability story plain: the moat has held through volume shocks and labor inflation, faces a quantified hospital-side headwind in 2026, faces a less-quantified hospital-side headwind in 2027, and faces a single under-tested USPI-side risk (Optum narrow-network exclusion) that — if realized — would erode the durable advantage faster than any of the other scenarios.

Where Tenet Healthcare Corporation Fits

The moat is concentrated in USPI, not in the corporation. Inside Tenet, the geography of advantage is specific: the 535 ASCs and 26 surgical hospitals across 37 states, the ~6,000 physician partners who hold equity in those facilities, and the high-acuity case mix (orthopedics, spine, cardiology, GI) that has been migrating from inpatient settings. Strip USPI out and Tenet is a mid-tier hospital chain similar to UHS or CYH — better-managed than CYH, less leveraged than SGRY, smaller and less dense than HCA, with no defensible advantage at the consolidated level.

Two things follow from the segment positioning. First, USPI is where the moat lives, but USPI is also where the highest growth, M&A capital deployment, and physician-partner cash leakage all sit — meaning the per-share value created by USPI's moat is materially less than its segment EBITDA suggests, because ~30% goes to NCI partners. Second, the hospital segment is the structural drag on the moat rating — it earns a market-rate return on capital, faces 2026 and 2027 policy headwinds, and competes directly with HCA in shared markets. The investment case is essentially that the (narrow but real) USPI moat can compound fast enough to outweigh hospital-segment commoditization.

What to Watch

Six signals that tell you whether the moat is widening, holding, or eroding. The first is the master indicator; the rest are confirming or refuting reads.

The Forensic Verdict

Tenet's headline FY2024 GAAP profit was structurally distorted, but the company is open about it: a $2.916B pre-tax "Net gains on sales, consolidation and deconsolidation of facilities" sits above the operating income line in the FY2024 income statement, lifting reported operating income by 51% and net income by roughly 6x in a single year before normalizing in FY2025. Underlying cash conversion looks acceptable (3-year CFO/NI 1.53x, 3-year FCF/NI 1.01x), receivables shrank in line with disposed hospitals, and capex/depreciation has finally re-crossed 1.0x. The forensic risks that earn this name a "Watch" — not "Clean" — sit in three places: the unusually permissive operating-income presentation of the divestiture gain, a 2025 short-seller allegation citing an active SEC enforcement matter, and a leadership transition in the accounting function (Principal Accounting Officer change effective May 1, 2026) layered on top of a multi-decade history of fraud settlements. The single data point that would most change this grade is whether the rumored SEC enforcement matter in Tenet's FOIA appeal results in charges, a settlement, or a non-public closure.

Shenanigans Scorecard - 13 categories

Breeding Ground

Tenet sits in a higher-than-average breeding ground for accounting risk, dominated by a long settlement history and management compensation tied to the very metrics under question. None of the 2025-2026 governance signals individually trigger an alarm, but the cluster matters when read together.

The compensation structure is the most consequential breeding-ground signal: long-term equity vests on Adjusted EPS, free cash flow, ROIC and relative TSR, while annual cash incentives reference Adjusted EBITDA and revenue. Each of those metrics is influenced by exactly the items this report examines (gain-on-sale presentation, Conifer cash flow timing, supplemental Medicaid recognition). That alignment is sector-standard but means the company's economic incentives are not neutral on accounting choices.

Earnings Quality

Underlying earnings quality is mixed. The clean side: revenue growth and receivables growth converged in FY2025, supplies and labor cost ratios are improving, and the capex cycle is stepping up rather than down. The unclean side: FY2024 GAAP operating income reported a 14.1 percentage-point margin tailwind that was entirely a $2.916B divestiture gain.

The FY2024 operating-income distortion

The $2,916M FY2024 line item — labeled "Net gains on sales, consolidation and deconsolidation of facilities" — sits inside the operating expense reconciliation and pushes operating income from a normalized ~$3,040M to a reported $5,956M. That presentation is GAAP-consistent for divestitures of a going concern, but it makes the income statement look as though hospital margins doubled in 2024. They did not. Adjusted EBITDA of $4.0B in 2024 versus $4.57B in 2025 is the more honest comparable.

Cash conversion vs reported earnings

Two anomalies stand out. FY2024 net income spiked to $3.2B because of the divestiture gain, while CFO actually fell to $2.05B — the gain is a non-cash accounting event so it does not pass through CFO. FY2025 then shows the inverse: CFO jumped to $3.54B, well above net income of $1.41B, mostly because cash income tax payments dropped $821M after absorbing the FY2024 gain-related tax bill. Across three years the picture normalizes (3Y CFO/NI 1.53x, 3Y FCF/NI 1.01x), but neither single year is a clean read on durable cash earnings.

Receivables vs revenue

This is one of the cleanest earnings-quality tests Tenet passes. Receivables fell 13% in FY2024 because divested hospitals took their AR with them — exactly what disposal accounting predicts. In FY2025 receivables grew only 1.1% versus 3.1% revenue growth, a favorable working-capital read. There is no sign of channel-stuffing or premature revenue recognition at the consolidated level.

Soft assets

Goodwill rose roughly $900M from FY2023 to FY2025 even as the hospital footprint shrank, reflecting USPI's rolling ASC acquisition program. Goodwill plus intangibles is now 42% of total assets — high but consistent with an acquisition-led ambulatory platform strategy. There is no impairment in recent periods. Worth monitoring because USPI multiples paid have stayed stretched in deal markets and an enrollment-driven volume miss could test goodwill assumptions in 2026.

Cash Flow Quality

Cash flow looks healthy but is bracketed by two distortions: a working-capital release as hospitals were sold in 2024, and an upcoming three-year boost from the Conifer transaction starting in 2026.

Working-capital and acquisition-adjusted FCF

After capex and acquisitions, FCF was $2.22B in FY2025, the strongest read in the cycle. But two adjustments shift the run-rate view:

• FY2025 cash taxes were $821M below FY2024 because the FY2024 gain pushed tax payments into that year. Normalize FY2025 cash taxes upward by roughly half of that one-time benefit, and FCF after acquisitions falls toward $1.8B.
• The Conifer transaction agreed January 27, 2026 brings $1.9B over three annual installments to Tenet — a contract buyout from CommonSpirit Health, not recurring service revenue. Booked through 2026-2028, it will lift CFO by roughly $600M per year before disappearing.

Accrual ratio

FY2024 turns positive at +4.0% — the warning sign — because $2.9B of non-cash gain landed in net income without a corresponding CFO inflow. FY2025 swings sharply negative (-7.3%) as cash earnings outrun GAAP earnings. Together they net out, but the year-by-year pattern is exactly what a forensic test should highlight: large divergence between accrual earnings and cash earnings.

Metric Hygiene

Tenet's non-GAAP framework is reasonable on paper but contains three definitional choices that flatter the headline picture.

Non-GAAP gap and adjusted EBITDA path

The three lines sit on top of each other in FY2024, then fan out in FY2025 — the textbook visual fingerprint of a one-time gain. Adjusted EBITDA tracks the underlying business; GAAP operating income and net income both jumped artificially in 2024.

What to Underwrite Next

The forensic risks around Tenet are real but bounded. They are valuation-relevant, not thesis-breaking, and the cash conversion math is acceptable when normalized. The five highest-value watch items:

1. SEC enforcement matter signaled by the Fuzzy Panda FOIA appeal. The 7(A) exemption response is consistent with an active investigation, not a closed one. Track 8-K filings for Wells notices, settlement disclosures, or required restatement language. Resolution materially upgrades or downgrades this score depending on direction.

2. Conifer cash flow recognition through 2026-2028. Verify the $1.9B is presented as operating cash flow (the natural place for a customer payment) and that management explicitly carves it out in adjusted FCF reconciliation. If presented inside CFO without segregation, treat headline 2026-2028 FCF as overstated by ~$600M annually.

3. 2026 Adjusted EBITDA bridge. Management's claim of 10% core growth depends on three normalizations: $148M out-of-period DPP added back, $40M Conifer one-time stripped out, and $250M PTC headwind absorbed. Watch Q1 2026 effectuation rates on exchange enrollment — Hospital segment is most exposed in Arizona, Michigan and California.

4. Accounting leadership transition. R. Scott Ramsey served as Principal Accounting Officer through April 30, 2026; J. Michael Grooms succeeds May 1. Long-tenured PAO transitions are a common moment for previously deferred adjustments to surface. Watch the FY2026 10-K for any change in critical accounting estimate language, reserve methodology, or revenue recognition disclosures.

5. Goodwill / intangibles trajectory in a soft-volume scenario. Soft assets are 42% of total assets. If 2026 hospital admissions disappoint by more than the company's 1-2% guide, USPI's $11.2B goodwill warrants impairment-test pressure. Specifically watch reporting unit fair value disclosures in the FY2026 10-K.

Signals that would downgrade the grade to Elevated (41-60): SEC enforcement proceeds publicly with a restatement requirement; FY2026 reveals Conifer cash classified ambiguously inside CFO; FY2026 reserve releases or impairment charges exceed the FY24-25 baseline.

Signals that would upgrade the grade to Clean (under 21): Public closure of the SEC matter without action; Conifer cash explicitly carved out of adjusted CFO; FY2026 Adjusted EBITDA delivers in line with guidance with no further normalization items.

Position-sizing implication. This is not a thesis-breaker. The forensic flags justify a valuation haircut of roughly 5-10% on EV/EBITDA versus a clean-balance-sheet peer, and a smaller initial position with active monitoring of the next two earnings releases. The largest risk is single-event — a regulatory action or restatement — rather than a slow erosion of earnings quality. Use Adjusted EBITDA, FCF after NCI, and acquisition-adjusted FCF as the three numbers that matter; ignore GAAP operating income for trend purposes.

Governance Verdict: B+

Tenet earns a strong-but-not-pristine governance grade. The board is genuinely independent (11 of 12), the comp program is structurally sound and shareholders ratified it with 93% support, and there are no related-party transactions. The drag is pay quantum, an entrenched Chair/CEO combo at the top, and a 12-month insider record that is all sells, no buys.

The People Running This Company

A McKinsey-trained physician-CEO with one publicly traded board seat (his own), a deep operating bench, and a Chairman/CEO who took the top job in 2021 and was given an $18M retention package in January 2025 to lock him in through 2028. Capability is not the issue here. The issue is concentration of authority — Sutaria is Chair, CEO, and the only insider on the board.

What matters for trust. Sutaria's resume is genuinely top-tier (UCSD MD, McKinsey senior partner specializing in healthcare delivery), and his 2021 takeover coincides with a portfolio repositioning that delivered the highest TSR in the four-name peer group over one, three, and five years. CFO Sun Park's pre-Tenet role at AmerisourceBergen Pharma Distribution gives him scale-finance credentials. COO Lisa Foo's promotion at age 35 — a former McKinsey associate partner with seven years inside Tenet — is unusually fast for a hospital chain and signals heavy CEO sponsorship of his own bench. The 2026 retention bonuses on Foo, Park, and Arnst (each clawback-able if they leave before May 2029) tell you the board sees concentrated key-person risk.

What They Get Paid

Pay is high in absolute dollars but tightly indexed to performance. Sutaria earned $43.1M in 2025 — a 75% jump driven by a one-time $7.2M retention RSU and a $10.8M retention PRSU layered on top of normal LTI. AIP funded at the 200% cap because Adjusted EBITDA ($4.566B) and Adjusted FCF less NCI ($1.842B) both hit maximum.

Is pay sensible? Yes, with caveats. The $149M "compensation actually paid" to Sutaria in 2025 reflects mark-to-market on equity awards as Tenet stock returned 497% cumulatively since end-2020 versus 148% for the S&P 500 Healthcare index — Tenet beat its peer group by 350 percentage points. The 2023 PRSUs vested at 225% of target because all three years hit maximum and the company ranked #1 against HCA, UHS, and CHS on three-year TSR. Pay genuinely tracks performance; the issue is level. The pay ratio of 1:711 is at the high end of large hospital operators, and the $4M special retention bonuses paid in May 2025 to Park, Arnst, and Foo (in addition to record AIP and equity) feel belt-and-suspenders given the ordinary LTI grants already vested.

Are They Aligned?

This is where the picture gets nuanced. Tenet has solid structural alignment (high stock ownership requirements, anti-hedge/pledge, no related-party transactions), but the behavior in the past 12 months has been one-sided.

Ownership map

Float is widely held. No strategic or activist owns more than 12.5%. There is no founder, no promoter, no controlling shareholder. The 16 named officers and directors collectively own 849,233 shares — under 1% of the 87.6M outstanding. The two largest beneficial owners are passive index funds (Vanguard + BlackRock = 21.9%), which generally vote with management and ISS recommendations.

Insider buying versus selling

The benign reading is portfolio diversification — Sutaria still holds 533,564 shares worth $106M and sat well above his 6x-base-salary requirement before and after his September sales. Officers used 10b5-1 plans, no Rule 10D pre-clearance issues are disclosed, and most "sells" by NEOs (March 2026) simply convert vested PRSUs into cash after the 225% payout. The unfavorable reading is that not a single director or officer has bought in the open market for over a year while the stock has gone from $159 to $239.

Dilution and grant burn

Total potential dilution under approved plans is ~10.8M shares against 87.6M outstanding — about 12.3% on a fully-loaded basis. RSUs reduce the 2019 plan reservoir at a 1.65x rate, which is shareholder-friendly. The company also repurchased 8.8M shares for $1.4B in 2025, meaning net share count fell. This is one of the strongest signals of capital-allocation alignment in the file: management is buying back stock at a faster pace than they are issuing it.

Related-party transactions

The proxy explicitly states "There were no 'related person' transactions that require disclosure under the SEC rules since the beginning of our last completed fiscal year." Joint-venture put/call structures with USPI partners are flagged as a risk factor in the 10-K (partner interests, exit rights, contractual put/calls), but no individual director or officer is named as a counterparty. The Sutaria employment agreement (Jan 2025) includes a non-compete covering only four named hospital competitors — narrower than typical — but this is a structural pay-package disclosure, not an RPT.

Skin-in-the-game scorecard

6 of 10. Plus marks for: CEO at 71x base in stock, all NEOs in compliance with 6x/4x/2x ownership multiples, anti-pledge/anti-hedge enforced, $1.4B in buybacks, no related-party transactions, no founder concentration. Drag from: zero open-market insider buys, $46M of one-way insider selling over 12 months, and combined Chair/CEO concentrating influence.

Board Quality

This is genuinely a high-quality board. Eleven of twelve directors are independent. The four-committee structure (Audit, HR, Governance, QCE) is standard, all chairs are women or veterans of regulated industries, and all committee members are independent.

Board matrix

Skill heatmap

The Verdict

Grade: B+. Tenet has a structurally clean, performance-linked compensation program; an 11-of-12 independent board with three audit financial experts and chairs who are competent and overwhelmingly female; no related-party transactions; anti-hedge and anti-pledge policies that are real and enforced; and a CEO with $106M of his own money in the stock. Capital allocation backs alignment — $1.4B repurchased in 2025 against ~$200M of equity issuance.

The strongest positives. Performance pays out only when peers are beaten — the 225% payout on the 2023 PRSUs required Adjusted EBITDA, FCF less NCI, and each one-year EPS hurdle to maximum, plus #1 TSR rank. 93% Say-on-Pay support is a real shareholder endorsement. Board refresh delivered six new independents since 2018.

The real concerns. Pay quantum at $43M for the CEO and $4M+ unbudgeted retention bonuses for three NEOs in May 2025 sit on top of an already-record AIP. Twelve months of insider activity is all sells, no buys — $46M out the door versus zero in. The combined Chair/CEO arrangement with Sutaria leaves only Senator Kerrey as the formal counterweight, and Kerrey is 82.

What would move the grade. Up to A-: a meaningful open-market insider purchase, formal separation of Chair and CEO when Sutaria's contract expires in 2028, or termination of the special retention bonus practice. Down to B: renewed insider selling at a comparable pace through 2026, a related-party transaction emerging at the next proxy cycle, or any compliance event under the QCE Committee's purview. The history of Tenet (the 2016 $513M Atlanta DOJ settlement, predating current management by half a decade) sets the bar for what "ethics oversight" has to mean here — and so far Sutaria's tenure has run clean.

The Narrative Arc

Five years ago Tenet was a 6.4x-levered, 65-hospital operator that the street had given up on; today it is a 50-hospital / 533-ASC platform levered at 2.25x with margins that have nearly doubled. The story changed through three distinct chapters — Rittenmeyer's "transformation" (2017–2021), Sutaria's quiet portfolio surgery (2021–2024), and the post-divestiture "predictability" pitch (2025–today). Management's credibility has improved materially: they raised 2021 guidance three times, hit nearly every leverage milestone, and over-delivered every quarter from 2023–2025. The two narrative items they quietly dropped — the Conifer spin and the "65-hospital growth platform" — were replaced with stories that turned out to be true.

1. The Narrative Arc

The two charts capture the entire turnaround in a single picture: leverage cut by two-thirds while EBITDA nearly doubled. The transformation pre-dates the pandemic in concept but was executed through it. Note the 2022 leverage uptick — that was a deliberate pause, not a setback, while management recycled Miami sale proceeds and absorbed contract-labor inflation.

2. What Management Emphasized — and Then Stopped Emphasizing

Topics rotated through prepared remarks at very different cadences. The heatmap below reads as a topic frequency timeline: dark cells are intense focus, faded cells indicate the topic was barely mentioned that year.

Three patterns matter:

• Conifer's strange life. The spin was the loudest 2020–2021 narrative; it then went silent for three years and reappeared in 2025 — but as a JV restructuring transaction, not a spin. Management never formally disowned the spin; it simply stopped being mentioned, and the segment was quietly folded into Hospital Operations in late 2023.
• Higher-acuity is the only theme that has been pushed harder every year since 2020. It has held up under scrutiny — case mix index ran 10–13% above 2019 levels in 2021, and net-revenue-per-case grew at MSD–HSD rates every year since.
• AI / automation went from background plumbing to the central margin-expansion thesis in 2025, replacing the older "labor management discipline" framing. Management is asking investors to underwrite a productivity story that is genuinely new.

3. Risk Evolution

The risk-factor section of the 10-K reorders almost every year. The cells below score how much weight each risk got in the year's filing and prepared remarks.

The risk profile reorganized completely between 2021 and 2025. Three observations:

• Two risks essentially evaporated. Leverage (refinancing wall, covenant pressure) is no longer mentioned. The Conifer spin execution risk vanished because the spin itself vanished.
• Three risks newly dominate. Premium-tax-credit expiration is now the single largest 2026 EBITDA variable ($250M headwind, quantified for the first time on the Q4 2025 call). OBBBA appeared in the 2025 10-K as an entirely new risk and is the first acknowledgment that Medicaid cuts could compress earnings through 2034. Site-neutral payment policy went from background mention to a specific item Sutaria addressed proactively in 2024 and 2025.
• One risk has steadily climbed for five years and is now structural. Payer denials and the back-and-forth around documentation requests went from a passing reference in 2021 to a "too high for what is appropriate" admission on the Q1 2026 call. Tenet's response — automating Conifer's denial workflow — is now a recurring growth story.

4. How They Handled Bad News

There are three episodes worth examining: the Conifer spin slip, the Q4 2024 revenue miss, and the 2026 exchange headwind.

5. Guidance Track Record

Only the promises that mattered to valuation, credibility, or capital allocation are scored below.

Why an 8 and not higher. Tenet's record on the things investors trade on — EBITDA, leverage, free cash flow, capital returns — is excellent and consistently exceeded the high end of guidance over the 2023–2025 stretch. The deductions are: (1) the Conifer spin commitment was abandoned without an explicit walk-back, leaving disclosure quality below where the operating record sits, and (2) USPI's ASC count target (575–600 by year-end 2025) was missed materially even as the ambulatory financial story over-delivered, suggesting the underlying narrative was occasionally calibrated to optics. Neither deduction undermines the operating thesis. Both indicate the language is more flexible than the numbers.

6. What the Story Is Now

The current story is small, clean, and durable: a 50-hospital, 533-ASC operator with 2.25x leverage, $1.6B–$1.83B of post-NCI free cash flow, ~70% commercial / managed-care revenue, and a margin profile (21.4% adj. EBITDA) that no peer matches at scale. USPI is the growth engine and is now insulated from the riskiest reimbursement debates (Medicaid, site-neutral inpatient/outpatient parity). Hospitals are smaller, more concentrated in higher-payer-mix markets, and increasingly carried by acuity rather than admissions volume.

What has been de-risked: balance sheet, refinancing cliff, COVID overhang, Conifer JV restructuring, and exposure to the most distressed Medicaid-heavy markets that the company has spent five years exiting.

What still looks stretched: the assumption that AI/automation and length-of-stay management can keep producing 100+ bps of annual margin expansion against a backdrop of 41% premium-tax-credit-driven exchange softness, OBBBA Medicaid policy, and a payer-denials environment management itself describes as "too high for what is appropriate." Hospital admissions guidance has been quietly trimmed twice in 18 months (2.5% → 1.5–2.5% → 1–2%); the implicit message is that hospital growth is now mostly a price/acuity story, not a volume one.

What to believe: the cost discipline, the USPI growth pipeline, the buyback cadence, the net-revenue-per-case trend, and the leverage profile.

What to discount: any specific 2026–2028 EBITDA bridge that depends on the OBBBA / exchange picture being clean — management has said directly that 2027–2028 policy is "an area of significant uncertainty." Treat their core 10% growth target as a base case, not a commitment.

Financials — What the Numbers Say

Tenet has spent the last five years rebuilding itself from a $15B-debt, single-digit-margin acute-care chain into a higher-margin operator with an outsized ambulatory engine. FY2025 revenue was $21.3B, but the right number to anchor on is EBITDA of $4.1B at a 19.3% margin — the cleanest measure of underlying profitability after the FY2024 divestiture noise washes out. Free cash flow of $2.5B in FY2025 is the highest in the company's history and converted at 180% of net income. Net debt has fallen to $10.3B (2.5x EBITDA) from a peak of 7.9x in 2015 — leverage is no longer the reason to avoid this name. Buybacks reduced share count by 16% over five years. The stock trades at 12.8x earnings, 7.9x EV/EBITDA, and 6.8x FCF at the FY2025 close — between value-stressed CYH/UHS and premium HCA. The single financial metric to watch right now is Hospital Operations EBITDA growth ex-divestitures — that is what proves the rerating is durable rather than a 2024 sugar-high.

Headline KPIs

How to read this page. Revenue is the top line. Operating income and EBITDA (earnings before interest, taxes, depreciation and amortization) measure profit before financial structure. Free cash flow is operating cash minus capex — the cash management can actually use. Net debt / EBITDA tells you how many years of profit it would take to repay debt; for hospital operators, anything under 4.0x is healthy and 2.5x is below average. ROIC (return on invested capital) measures dollars of after-tax operating profit per dollar of capital deployed — for a US for-profit hospital, double-digit ROIC is good.

Revenue, Margins, and Earnings Power

Tenet's revenue chart tells two stories on one timeline. The 2013–2020 era — built around the Vanguard merger and large hospital footprint — produced revenue near $18–20B with operating margins stuck in a 5–8% band. The post-2020 period, after USPI was scaled and underperforming hospitals divested, shows margins stepping up to a sustainably double-digit level.

The FY2024 spike on operating income and EBITDA is a divestiture gain, not earnings power. The honest signal is the sustained step-up from 2020 onward: EBITDA went from $2.2B in 2019 to $3.5B in 2021 and now $4.1B in 2025, a 15%+ CAGR through a period of essentially flat hospital revenue — almost all the gain is mix shift toward USPI ambulatory and pricing/cost discipline in Hospital Operations.

Gross margin has crept up from ~36% to ~41% as ambulatory revenue (which carries higher contribution margins) replaces low-acuity hospital admissions. Operating margin and EBITDA margin doubled from the 2015–2017 trough — that is the durable change. Net margin still bounces around because of two below-the-line items: interest expense (~$800M annually on $13B of debt) and minority interest (USPI hospitals/ASCs have meaningful non-controlling interests, which is why "consolidated" net income is materially higher than net income to Tenet shareholders).

Recent quarters confirm the run-rate: revenue around $5.3–5.5B per quarter and operating income around $770–890M in clean quarters. Q1 FY26 op income of $1,245M includes another modest divestiture gain (SC hospitals, March 2026). Reported Q1 FY26 EPS of $4.82 beat the $4.21 consensus and management raised FY2026 EPS guidance to $16.38–$18.68, which would imply 5–20% earnings growth on a high FY2025 base.

Cash Flow and Earnings Quality

The earnings-quality question for Tenet has historically been the same: do the reported profits become cash? For most of the 2010s the answer was no — high D&A, working-capital absorption, and constant capex on a 60+ hospital footprint meant operating cash flow swallowed most of the GAAP profits. That story flipped in 2020 and has held since.

Free cash flow = operating cash flow minus capital expenditure. It is the cash management can use to repay debt, buy back stock, pay dividends, or make acquisitions — without raising new capital.

Three things stand out:

1. FY2020 was inflated by COVID provider relief and CARES Act payment timing (large positive working-capital swing plus deferred payroll tax). That $2.9B FCF is not a fair baseline.
2. FY2025 FCF of $2.5B is the cleanest peak. Operating cash flow of $3.5B less capex of $1.0B leaves a $2.5B prize, and net income of $2.4B converts at >100%.
3. FY2024's smaller FCF ($1.1B) is misleading the other way — Tenet pre-paid taxes on the divestiture gains, suppressing operating cash flow that year, and the gain itself was non-cash (it sat in operating income but the cash showed up in investing).

The reader's takeaway: FY2025 is the first year in Tenet's modern history where reported profits, operating cash, and free cash all line up at high levels. There is no longer a meaningful gap between accounting earnings and cash earnings — and that is the single biggest structural change behind the rerating.

Balance Sheet and Financial Resilience

Tenet was, for most of the post-Vanguard era, a balance-sheet stress story. Total debt north of $15B, EBITDA below $2.5B, and shareholders' equity at one point negative. The chart below is the single most important picture on this page.

The red line collapsing from ~8x to ~2.5x over a decade is the deleveraging story. The FY2024 reading of 1.56x is artificially low because it divides through divestiture-boosted EBITDA; on a clean FY2025 basis, leverage is 2.5x — still meaningfully below the 4–6x range of the prior decade.

Three resilience reads. Liquidity: $2.9B cash plus an undrawn revolver and 1.76x current ratio leaves Tenet able to cover any near-term debt maturity from the balance sheet. Coverage: EBITDA covers interest 5.0x — comfortable for a B+/BB-rated hospital operator and a step-change from 1.8x in FY2017. Flexibility: with leverage near 2.5x and an investment-grade-adjacent profile, Tenet now has optionality for either accelerated buybacks, USPI bolt-on M&A, or a small acquisition.

The remaining structural risk is goodwill and intangibles of $12.5B against tangible book of negative $3.6B — meaning if anything went wrong with USPI's cash-generation profile, there is no asset cushion. That is why the cash-flow trend is so important: as long as USPI keeps producing, the goodwill is "supported"; if it stops, Tenet would be back in a stress scenario.

Returns, Reinvestment, and Capital Allocation

The case that Tenet is creating real value (rather than just inflating the headline through buybacks) rests on the return-on-capital chart. Here is what dollars of capital are actually earning.

ROIC = after-tax operating profit / invested capital. ROE = net income / equity. ROA = net income / total assets. ROE looks high partly because equity was small or briefly negative through 2017–2020 — denominator effect, not operating quality. ROIC is the clean metric here.

ROIC of 11.4% in FY2025 is genuinely good for a hospital operator (the long-term industry average sits in mid-single digits). It is also above Tenet's own cost of capital, which is roughly 8–9% for a company with this leverage and beta. The 18.3% reading in FY2024 was divestiture-inflated — strip out the gains and FY2024 ROIC was ~9–10%, broadly continuous with FY2025.

The mix has tilted hard toward shareholder returns. Buybacks went from zero through 2020 to $1.4B in FY2025 — the largest in company history and roughly equal to that year's net income. Acquisitions remain modest bolt-ons rather than transformational deals. Capex has crept up to $1.0B (4.7% of revenue), funding USPI center build-outs.

Diluted share count fell from 106.8M in FY2021 to 90.2M in FY2025 — a 15.5% reduction, all while the stock price more than doubled. That is the textbook definition of intelligent capital return: returning capital when the leverage allowed it and when the stock was below subsequent fair value. Per-share EPS in FY2025 of $15.49 is roughly double what the company has reported in any clean year.

Segment and Unit Economics

The segment file in data/financials/segment.json was not retrievable in this run. From the FY2025 10-K and management's reporting, Tenet operates two reportable segments — Hospital Operations & Services (acute-care hospitals + ancillary services) and Ambulatory Care (USPI: 500+ surgical centers, surgical hospitals, and imaging centers). The economic split, based on company disclosures referenced in upstream research, is approximately:

The pattern that matters for the equity story: Ambulatory Care produces ~21% of revenue but close to 45% of segment EBITDA, at margins more than 2.5x the Hospital Operations segment. Every incremental dollar Tenet rotates from low-acuity hospital admissions into high-acuity ambulatory cases lifts blended margin, and that is exactly what management has been doing for five years. The segment economics also explain why peer pure-play ambulatory operators like SGRY trade at ~9.4x EV/EBITDA versus stressed acute-care peers at 5–6x — Tenet's EV multiple should be a weighted average, and it is.

Note: these are estimated splits from management commentary in upstream research files; the run's segment.json did not return values, so the precision is limited. The directional point — USPI does most of the heavy lifting on profitability — is well-corroborated across upstream agents.

Valuation and Market Expectations

The right valuation question is not "is THC cheap?" but "what is the market pricing this business at, given growth, margin, leverage and cash conversion?" Three multiples answer that.

The negative-P/E years (2015, 2016, 2017, 2019) are when Tenet had GAAP losses; meaningful only as a marker that the multiple was undefined. The clean read is the EV/EBITDA line, which sat in the 7.5–11.0x band for a decade and is now at 7.9x — middle of the historical range. The 4.1x reading in FY2024 is divestiture-inflated EBITDA again — discount it.

Reading the scenarios: Multiplying FY2027E EBITDA (in $B) by an EV/EBITDA multiple gives EV; subtract net debt of ~$10.3B to get equity; divide by ~90M shares for an indicative price. Scenarios use round numbers — they are valuation scaffolds, not precision forecasts.

The current price of roughly $187 sits at the midpoint of the base case — neither obviously cheap nor obviously expensive. Sell-side targets cluster in the $210–$260 range (consensus around $240, MarketBeat 19 Buy / 3 Hold / 1 Strong Buy), suggesting the Street is closer to the base/bull line. The bear case is real if FY2026 admissions mix (flagged as soft in Q1 FY26) keeps deteriorating; the bull case requires continued ambulatory mix shift plus another round of buybacks at sub-$200.

Peer Financial Comparison

Choose the right peer for the question: HCA is the scale benchmark, UHS and CYH are direct hospital comps, SGRY is the only listed ambulatory pure-play, and ACHC is a stressed specialty operator.

The peer gap that matters. Tenet earns a higher EBITDA margin (19.3%) than UHS (15.0%) and CYH (15.3%) and is closer to HCA's premium 20.5%. Yet Tenet trades at 7.9x EV/EBITDA — one full turn below HCA's 9.2x and roughly one turn above the stressed UHS/CYH multiples. The market is pricing Tenet as "almost-HCA" but not quite: the discount makes sense if you doubt the durability of USPI's margin contribution, and looks too wide if you trust it.

The scatter shows the relationship cleanly: hospital operators get paid for margin and scale. Tenet is the second-most profitable operator in the peer set after HCA, sized between UHS and HCA, and priced slightly below where its margin alone would warrant. There is room for a half-turn rerating if FY2026 numbers hold, but no obvious value gap that lasts beyond that.

What to Watch in the Financials

Binder Error: Set operations can only apply to expressions with the same number of result columns

What the financials confirm. Margins have stepped up to a sustainably higher level. Cash conversion is now strong. Leverage is fixed. Returns on capital are above cost of capital. Capital is being returned to shareholders intelligently. The business has rebuilt its right to a "normal" multiple.

What they contradict. The bull narrative of "USPI compounding" is not yet visible in segment-level financials with the granularity an analyst would like — segment data was not available in this run, and the picture must be triangulated from full-year EBITDA and management commentary. Hospital-Operations growth, ex-divestiture, looks closer to flat than growing; if USPI ever decelerates, blended growth disappears.

The first financial metric to watch is Hospital Operations EBITDA growth ex-divestitures. If it prints at +5% or better in FY2026 — proving the legacy hospital book is genuinely earning more, not just shrinking gracefully — Tenet earns a HCA-style 9.0x+ multiple and the stock has 15-25% upside from here. If it goes flat or negative, the bull case rests on USPI alone, the multiple compresses to UHS levels, and the stock has 10-15% downside. Everything else on this page is essentially a corollary of that single line.

Web Research

The Bottom Line from the Web

The single most important fact the internet adds beyond the filings is the CommonSpirit/Conifer Omnibus Agreement (signed January 27, 2026): CommonSpirit pays Tenet ~$1.9B over three years to terminate the RCM contract early, while Tenet redeems CommonSpirit's 23.8% Conifer stake for $540M and regains 100% of Conifer. Tenet recognized $413M of revenue from early contract conclusion in Q1 2026 alone — accretive today, but the contract winds down by year-end 2026 and creates a 2027+ revenue gap at Conifer. Layered on top: an ACA exchange premium tax credit expiration that management has sized at a $250M 2026 EBITDA headwind, ongoing USPI ambulatory-care momentum (Q1 EBITDA +6%, $125M deployed on 7 ASCs), and labor/patient-safety controversies at St. Vincent Hospital in Massachusetts that the filings don't fully surface.

What Matters Most

1 — CommonSpirit pays Tenet ~$1.9B to exit the Conifer RCM contract

CommonSpirit Health (the former Catholic Health Initiatives) signed an Omnibus Agreement on January 27, 2026 paying Tenet ~$1.9B over three annual installments (with $540M satisfied at closing). In a separate leg, Conifer redeems CommonSpirit's 23.8% equity stake for $540M and reduces redeemable noncontrolling interests by ~$885M. Conifer's services to CommonSpirit continue at existing terms through end-2026 and then terminate. The deal is accretive in 2026 and de-leverages the balance sheet, but it removes Conifer's largest external client from the 2027+ revenue base — making client backfill the key Conifer execution risk.

2 — ACA premium tax credit expiration: $250M 2026 EBITDA headwind, 20% enrollment decline assumed

CFO Sun Park sized the 2026 hit at "$250 million on our 2026 adjusted EBITDA, primarily in the hospital segment." Management is assuming a 20% reduction in overall ACA exchange enrollment, with disproportionate exposure in Arizona, Michigan, and California. Tenet's expected hit is materially smaller than peer HCA Healthcare, which has guided to a $900M–$1B 2026 EBITDA hit from the same lapse. The Q1 print indicates Tenet's actual exchange admission decline (~10%) is running below the 20% guided number — a potential upward revision lever later in 2026.

3 — USPI continues to compound; Inpatient-Only list phase-out is the structural tailwind

USPI delivered Q1 adjusted EBITDA of $484M (+6% YoY) at a 36.7% margin (vs. 38.2% prior-year, partly weather/cyber-attack-related), with 5.3% same-facility revenue growth and double-digit growth in joint replacements. Tenet deployed $125M on seven ASC acquisitions in Q1 alone — half of its $250M full-year USPI M&A target — and added three de novos. The CMS CY2026 OPPS/ASC proposed rule (issued July 15, 2025) eliminates the Inpatient-Only list over a three-year transition, expanding higher-acuity procedures available to ASCs. CEO Sutaria has framed this as the multi-year tailwind underpinning USPI's mix shift to higher-acuity, lower-volume cases. Sources: Q1 release, ASC News 2026-02-11, HK Law CY2026 OPPS analysis.

4 — St. Vincent Hospital (Worcester, MA): labor violations + Immediate Jeopardy patient-safety findings

A judge ruled on February 17, 2026 that Saint Vincent Hospital — a Tenet-owned facility in Worcester, MA — committed over a dozen labor violations, including withholding bonuses and bypassing the union; the hospital must reimburse nurses and end the infractions. Separately, the Massachusetts Nurses Association in August 2025 publicized a DPH/CMS report that found St. Vincent administration "placed all patients in Immediate Jeopardy of serious harm, resulting in at least three patient deaths and other complications." The Joint Commission separately flagged in June (per the union release) that Tenet failed to meet care standards in its corrective action plan. None of this rises to corporate-level material in scope, but it is the most significant reputational/quality-of-care signal in the recent web record and is not in the Tenet earnings narrative.

5 — Sell-side target divergence: Baird cuts target to $210; RBC stays bullish; intrinsic-value models point higher

Baird cut Tenet's price target to $210 from $245 (a $35 reduction; rationale not disclosed publicly). RBC's Ben Hendrix reiterated Buy at $189 in mid-2025, calling Medicaid supplemental-payment policy concerns "overdone." Independent screen AlphaSpread's intrinsic-value framework places base-case fair value at $312 (40% undervalued vs. spot), combining a $263 DCF and $361 multiples-based view. CNBC shows TTM P/E of 9.76, forward P/E 10.78, EBITDA TTM $5.06B, ROE 37.87% — a value/quality divergence the consensus has not resolved.

6 — CEO Saum Sutaria sold $15M in stock in September 2025; total compensation ~$43M

On September 10, 2025, CEO Saumya Sutaria sold 78,762 shares (~$15M at then-prevailing prices), leaving him with 368,683 shares. He also exercised options and sold ~$1.3M of stock on March 3, 2026. Per Simply Wall St, Sutaria's total annual compensation is $43.1M (3.5% salary / 96.5% equity-and-bonus); the AFL-CIO previously placed him among the highest-paid healthcare CEOs. He owns ~0.61% of the company (~$96M). The web record does not surface a 10b5-1 plan filing for the September 2025 sale — that question remains unresolved.

7 — Governance and accounting transitions: director resignation, Controller hand-off

Director Stephen H. Rusckowski resigned effective November 24, 2025 (announced Nov 21, 2025); the board reduced from 13 to 12 members. The 8-K does not state a reason. Senior Vice President & Controller (Principal Accounting Officer) R. Scott Ramsey retires April 30, 2026 with a part-time transition role through March 31, 2028; on March 25, 2026 the board appointed J. Michael Grooms (formerly Lifepoint Health) as successor at a $475K base salary with $500K initial RSU grant. Ramsey sold 13,322 shares (his entire direct holding, ~$2.7M) on November 6, 2025. Sources: stocktitan.net 8-K, Investing.com Form 4, TipRanks 2026-03-31.

8 — Commercial rate updates locked in through 2027 — pricing power confirmed

This is a positive signal that runs against the broader commercial-payer narrative and supports the hospital-segment 16-17% EBITDA margin durability through the EPTC/OBBBA window.

9 — Hospital segment payer-mix degradation is real, but cost discipline is offsetting

Hospital Q1 net operating revenues grew only 0.5% YoY; same-hospital revenue per adjusted admission declined 1.5%. A 41% drop in respiratory cases compounded the seasonal/payer-mix pressure. Hospital segment EBITDA was $678M at 16.7% margin — better than feared given the headwinds, with consolidated salaries/wages/benefits as a percent of revenue improving slightly to 40.5% from 40.6%. Sources: Benzinga 2026-04-30, Investing.com Q1 slides.

10 — OBBBA Medicaid state-directed payments are the open 2027 variable

The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 restricts Medicaid state-directed supplemental payments. Tenet is recording ~$1.1B–$1.2B in supplemental payments in 2025 (Q1 2026 = $304M). Management has declined to quantify a 2027 impact. RBC views the market reaction as overdone; HFMA and others view OBBBA as the most material multi-year hospital-margin variable not yet priced. Source: Healthcare Dive, HFMA OBBBA briefing.

Recent News Timeline

What the Specialists Asked

Governance and People Signals

The pattern shows steady selling across the senior team without a single notable insider buyer in the last 12 months. The PAO sold his entire direct holding (~$2.7M) eleven months before retiring — bookkeeping behavior that is consistent with a planned exit but warrants noting alongside the leadership transition. CEO Sutaria's $15M September 2025 sale is the largest single insider event; his ~0.61% ownership stake (~$96M) remains substantial, so alignment is preserved.

Industry Context

Commercial-rate environment is unusually favorable for hospital operators. While UnitedHealth and other large payers are squeezed by elevated MA utilization, Tenet has secured commercial rate updates through 2027 above prior-year levels — running counter to industry chatter about Medicare Advantage contract dustups (Lehigh Valley/UHC). This pricing power is partially priced in but supports Tenet's hospital-segment 16-17% EBITDA margin durability.

Inpatient-Only list phase-out is the structural ASC tailwind. CMS proposed eliminating the IPO list over a three-year transition starting CY2026. Procedures historically restricted to inpatient settings (joints, spine, urology) become eligible for ASC reimbursement, expanding the addressable case mix for USPI. Tenet quantifies it as a multi-year tailwind without a single-year EBITDA size — directionally bullish but not bookable in the model yet.

ACA exchange premium tax credit expiration is the single biggest 2026 industry variable. Tenet's $250M EBITDA hit guide is on the lower end vs. peers (HCA: $900M–$1B). Q1 actuals (10% exchange admission decline vs. 20% guided) suggest Tenet's number may be conservative. KFF and other independent estimates cluster around 15-25% enrollment loss nationally, with state-level variance — Tenet's AZ/MI/CA exposure makes it slightly above-average exposed.

OBBBA Medicaid state-directed payment caps are the open 2027 variable. The "One Big Beautiful Bill Act" signed July 2025 restricts state-directed supplemental payments. Tenet recorded ~$1.1B–$1.2B in 2025 supplementals; 2027 phase-in could be material. Management has declined to size the impact. RBC views the market reaction as overdone but the policy text is binding.

ASC consolidation is accelerating. Tenet deployed $125M on 7 ASC acquisitions in Q1 2026 alone. HCA holds 121 ASCs + 31 endoscopy. SCA Health (private, Optum/UNH-owned) and SGRY (public) are the principal competitors. The CY2026 OPPS rule retains hospital-market-basket update for ASC payments through CY2026 — a one-year extension that compresses the site-of-service arbitrage but does not eliminate it.

Where We Disagree With the Market

The sharpest disagreement is on FY2027, not FY2026. Sell-side consensus has anchored FY2027 EPS at $17.76 against an FY2026 number of $17.72 — a flat-line that simultaneously requires hospital EBITDA to take a $300–500M OBBBA Medicaid hit, the buyback flywheel to stall, and USPI same-facility growth to decelerate to the lower band, all in the same year. Each piece is plausible in isolation; the joint probability is not. The buyback math alone — at the FY2025 cadence of ~$1.39B annual repurchase against a ~$17B market cap — mechanically retires roughly 7–8% of the float and should lift per-share earnings even in a flat consolidated EBITDA scenario. Where we disagree is not direction (sell-side already sits at $240 vs. a $187 tape) but what the FY2027 anchor is implicitly worth — and the resolving signal is observable inside the next two earnings cycles.

A secondary disagreement runs in the opposite direction: the headline 10% FCF yield is real on paper but ~30% smaller after physician-JV distributions and the non-recurring Conifer contract buyout. Passive screens treat a $2.5–2.8B FCF guide as durable; the underlying owner-level cash flow is closer to $1.6–1.83B and the FY2026–2028 prints are inflated by ~$600M annually of one-time CommonSpirit cash. That gap is what makes the bull SOTP narrative deserve a haircut even if the FY2027 anchor is too low.

Variant Perception Scorecard

The 62 variant strength reflects three things at once: a clearly observable consensus signal (the FY2027 EPS line frozen one cent above FY2026 by 17–18 analysts), a quantifiable mechanical disagreement (buyback math + USPI mix), and a binary resolution path (OBBBA implementation rules in H2 2026 + management 2027 commentary at the Q3 call). It is not 80+ because the lead disagreement is bracketed by a real bear-side disagreement on FCF quality, and because USPI same-facility growth has to print at or above 5% for two consecutive quarters to validate the bullish leg.

Consensus Map

The cleanest consensus signal is the FY2027 EPS line — 18 sell-side analysts have collectively held it within one cent of FY2026, despite raising the FY2026 guide and acknowledging that EPTC ($250M, 2026) and OBBBA ($300–500M, 2027) are stacked headwinds on the same hospital book. The consensus map shows where that uncertainty lives: not in any single model assumption, but in an unwillingness to adjudicate the joint probability.

The Disagreement Ledger

Disagreement 1 — FY2027 EPS is anchored too low

The consensus view is that FY2027 EPS should print roughly flat to FY2026 because OBBBA Medicaid implementation and a stabilized hospital book together cancel out USPI growth and buybacks. Our evidence disagrees: the buyback math alone — $1.4B annually at the FY25 cadence against a $17B market cap — mechanically retires roughly 7–8% of the float per year, lifting per-share earnings even in a flat consolidated EBITDA case. Layer on top USPI's 76% commercial/Medicare mix (structurally insulated from Medicaid policy) and management's 2025 cost-discipline trajectory (SWB at 40.2% in Q4, best-in-class versus HCA ~41–42% and UHS ~46%), and a $300–400M hospital EBITDA hit from OBBBA still leaves per-share earnings growing 8–12% from FY2026. If we are right, consensus would have to concede a $1.50–$2.00 FY2027 EPS reset and roughly half the $187-vs-$240 PT gap closes on the numerator alone. The cleanest disconfirming signal is management refusing to provide directional 2027 commentary at the Q3 2026 call — that would tell us OBBBA exposure is bigger than we model.

Disagreement 2 — Hospital margin floor is ~16%, not the ~14% bear case embeds

The consensus view treats Q1 2026's same-hospital RPAA of -1.5% as evidence that the post-divestiture margin reset is fragile and that hospital EBITDA margin compresses 200 bps as exchange and Medicaid mix erode commercial. Our evidence disagrees: the 16.7% Q1 hospital margin already absorbs the EPTC step-down, commercial rates have been publicly described as "secured through 2027 above prior years," and the kept hospital portfolio is concentrated in TX/FL non-expansion-state markets where commercial payer mix is structurally stickier than the consolidated peer set. The bear is right that exchange admissions remain a 2026 headwind; we disagree on how much of that flows to margin, because (a) the kept facilities have higher commercial-share floors and (b) state-directed payment caps in OBBBA hit expansion-state programs harder than the non-expansion programs Tenet relies on. If we are right, ~200 bps of defended hospital margin is worth ~$300M of segment EBITDA — roughly $2–3B of equity value at 6–7x. The cleanest disconfirming signal is two consecutive quarters of hospital RPAA below -2%, or SWB ratio re-expanding above 41%.

Disagreement 3 — The "10% FCF yield" overstates owner-level economics by ~30%

This one runs against the bull. Independent valuation screens (AlphaSpread base case $312, ~40% undervalued) anchor on the FY2026 FCF guide of $2.5–2.8B and back out an attractive headline yield. Our evidence disagrees: ~$700M of segment cash leaks to noncontrolling-interest distributions before equity holders see a dollar (FY26 guide post-NCI: $1.6–1.83B), the $1.9B CommonSpirit-Conifer payment is a one-time contract buyout that inflates 2026–2028 CFO by ~$600M annually then disappears, and FY25 cash-taxes ran $821M below FY24 because the divestiture-gain tax bill was paid in the prior year. Strip those three out and durable owner-level FCF is closer to $1.7B — a ~9% equity yield rather than ~13%. Consensus would have to concede that the right multiple frame is closer to fair value than deep value, which doesn't break the bull case but caps the rerate beyond ~$220. The cleanest disconfirming signal is FY2026 reported FCF after NCI printing toward the high end of the $1.6–1.83B band with Conifer cash explicitly carved out — a sign the run-rate is genuinely $2.0B+.

Evidence That Changes the Odds

The evidence that does most of the work is items 1, 4, and 6. The flat FY2027 line is the consensus signal we are calling out; the geographic mix is the under-appreciated structural cushion against OBBBA; and the Conifer cash is the one-time contamination of headline FCF that limits how far the bull case can run. Items 3 (buyback) and 8 (Q1 conservatism) provide the mechanical bridge to the higher FY27 number.

How This Gets Resolved

The decision is resolved inside two quarters. Q2 2026 earnings (late July) update the FY26 guide and the hospital-margin trajectory; Q3 2026 earnings (late October) deliver the first directional FY2027 commentary; and CMS/Treasury OBBBA rules in H2 2026 bound the worst-case hospital scenario. None of this requires waiting five years for the moat to be tested — every leg of the variant view has a dated, observable signal.

What Would Make Us Wrong

The lead disagreement breaks if any one of three things happens. First, OBBBA implementation rules issued in H2 2026 bind state-directed payments more aggressively than we model — specifically, if Texas and Florida provider-tax programs are re-classified as state-directed payments under the new framework, the hospital EBITDA hit can reach $500M annually rather than the $300M we treat as the realistic case. This would push FY2027 EBITDA below FY2026 and the consensus flat-line stops looking too low. Second, the buyback cadence stalls. If management redirects $500M+ of FY26 capital to a meaningful USPI M&A deal (e.g., to backfill the 533 vs. 600 unit miss) or to balance-sheet preservation ahead of an SEC enforcement resolution, the mechanical EPS lift we lean on disappears and the FY27 anchor becomes harder to dispute. Third, USPI same-facility growth prints below 5% for two quarters running. Q1 was 5.3% — close to the bear edge. If Optum/SCA Health begins systematically excluding USPI ASCs from UnitedHealth narrow networks, same-facility growth could compress to 3% and the segment EBITDA growth that funds the variant FY27 bridge collapses.

The hospital margin floor disagreement breaks if commercial rates start to crack — specifically if any of the active payer disputes (Cigna/Abrazo, Humana renegotiations) extends into a network exclusion or rate-cut settlement, or if the "secured through 2027" language proves to be top-line guidance that comes with give-backs on volume share. The same-hospital RPAA at -1.5% in Q1 needs to stabilize at flat by Q3 for our hospital floor case to hold.

The FCF-quality bear-side disagreement breaks if Conifer wins a major 2027 client backfill — a large health-system RCM contract announced before year-end 2026 would partially offset the CommonSpirit cliff and lift durable post-2028 FCF, narrowing the gap between headline and owner-level cash flow. It also breaks if management buys out a meaningful slice of the USPI physician-JV minority stake at a reasonable multiple, which would reduce NCI leakage.

We are most likely to be wrong on the lead disagreement if the SEC FOIA 7(A) enforcement matter becomes public — that is a re-rate event independent of operating fundamentals, and it would dominate any FY2027 EPS reset for at least two quarters of headline risk.

The first thing to watch is the Q3 2026 earnings call commentary on FY2027 — specifically whether management offers a quantified or directional 2027 EBITDA bridge that incorporates a non-zero OBBBA assumption. That single disclosure resolves whether consensus holding the FY2027 EPS line one cent above FY2026 is the analytically correct answer or the lazy one.

Liquidity & Technical

A 5% position is implementable for funds up to roughly $5.7B at a 20% ADV pace, clearing in five trading days — liquidity is not the bottleneck for any institutional sleeve. The tape is constructive on a multi-year basis (5y +236%, 3y +165%, 1y +35%) but has rolled over near-term: price sits 4.7% below the 200-day for the first time since the June 2025 golden cross, RSI is neutral at 47, and the most important feature is whether MACD histogram's recent flip back to positive is a genuine bottom or a counter-trend bounce inside a deeper distribution.

Portfolio implementation verdict

Price snapshot

The one-year tape is still positive but the stock has shed roughly 23% from the 52-week high of $244.80 set within the past twelve months and now sits in the lower half of that range. Realized volatility around 35% is in the lower-half of the 10-year regime — there is no panic in the price action, just drift.

The critical chart — 10-year price with 50/200 SMA

Price is below the 200-day by 4.7% as of the latest close. Read the chart this way: a decade-long secular uptrend (from $28 in 2016 to a $244.80 peak in 2025), interrupted by a clean six-month distribution that now has price flirting with the 200-day support. This is a pullback inside an uptrend, not a regime change — yet.

Relative strength vs benchmarks

In absolute terms, $100 invested three years ago is worth $262 today — a 161% gain that materially outpaces the broad U.S. equity market over the same window. Even after the recent pullback, the three-year line remains in a clear uptrend, with the recent fade only retracing roughly 20% of the prior advance.

Momentum — RSI and MACD

RSI at 47 is neutral — neither overbought nor oversold, and unable to confirm either direction. The MACD histogram has just flipped positive in the last few sessions (+0.64) after running deeply negative for months, but the MACD line remains far below zero (-5.23 vs signal -5.88). The honest read: momentum has bottomed locally, but a single positive histogram print is a setup, not a confirmation. Watch for the MACD line itself to cross above signal (it has) and then climb above zero (it has not).

Volume, volatility, and sponsorship

Volume action is unremarkable — the recent 12 months show daily activity hugging the 50-day moving average with no conviction-trade spikes, which is consistent with a stock that is drifting rather than being actively re-rated. The three lifetime volume events are all from prior cycles and skewed to the downside, including the 31% Q3 2022 earnings collapse that was the single largest negative print of the past decade.

Recent realized volatility of 35% sits between the 10-year 20th percentile (32%) and median (44%) — a calm-to-normal regime. The market is not pricing in stress; it is repricing slowly. That distinction matters: when distribution happens at low realized vol, it tends to extend further than people expect because there is no climactic flush to mark the bottom.

Institutional liquidity panel

This stock is a regular for institutional accounts. Annual share turnover of 341% means the entire float changes hands more than three times each year. Median daily range of 1.55% is modest — not a tight microcap and not a whippy growth name.

A. ADV and turnover strip

B. Fund-capacity table

How much fund AUM can THC support at common position weights, given five trading days to build the position?

A $5.7B-AUM fund can build a 5% position over five trading days at a 20% ADV cap. A more conservative 10% ADV cap halves that — supporting up to a $2.8B fund at a 5% weight. For a $10B-plus shop, the math forces either a smaller weight, a longer build window, or block execution.

C. Liquidation runway

How fast can a sized issuer-level position be exited at constrained participation?

D. Daily-range proxy

Median 60-day daily range is 1.55% — modest. Below the 2% threshold that would flag elevated impact cost. Bid-ask cost is not the binding constraint on size; participation discipline is.

The bottom line: at 20% ADV the largest issuer-level position that clears in five days is roughly 1.0% of market cap ($170M, 908K shares). At a more conservative 10% ADV the limit drops to 0.5% of market cap ($85M). For mainstream long-only and L/S funds, this is a fully tradable name; for very large multi-strategy platforms, the position is sized by participation rate rather than by conviction.

Technical scorecard and stance

Stance: NEUTRAL on the 3-to-6 month horizon, with a constructive structural bias. The multi-year uptrend remains intact (50-day above 200-day, golden cross since June 2025) and the longer absolute return profile is one of the strongest in U.S. health-care services. But the recent six-month tape has been a quiet distribution: price has rolled below both the 50-day and the 200-day, RSI cannot lift above 50, MACD has only just flipped to a hesitant positive histogram, and volume offers no buying climax. Two specific levels frame the next move:

• Above $205 (50-day SMA) — a clean reclaim with the MACD line crossing above zero would confirm the pullback is over and re-engage the multi-year trend. That is the add signal.
• Below $172 (recent support) — a close below this level would mark the death cross as the dominant signal, with a measured next stop near $160 and the 52-week low of $137 in play. That is the trim/exit signal.

Liquidity is not the constraint. A $5.7B-AUM fund can build a 5% position in five trading days at 20% ADV; the binding question for action is the tape, not capacity. Implementation guidance: watchlist for funds under $2B AUM with conviction in the long-term hospital thesis (build slowly into a 50-day reclaim); for size-aware multi-strategy books, wait for the price-vs-200d to flip back positive before sizing up.